Publications by authors named "J Devincenzo"
Creating Time and Space for the Intersection of Climatological Disasters and Racial Inequalities Curricula in the Classroom.
Disaster Med Public Health Prep
January 2025
Racial disparities and climatological disasters are complex topics rarely addressed in K-12 curricula. Each topic has long been neglected vis-à-vis a pedagogy that has either lagged behind contemporary issues or has intentionally sidestepped the importance of addressing these themes through legal and policy mechanisms that limit educators' ability to discuss each topic. When it comes to students and communities of color in the U.
View Article and Find Full Text PDFBackground: EDP-938 is an oral once-daily RSV nucleoprotein (N) inhibitor with potent antiviral activity. In a human RSV challenge trial, EDP-938 significantly reduced viral load and symptom severity. During antiviral development, it is critical to understand the propensity for resistance to develop.
View Article and Find Full Text PDFBackground: Monoclonal antibody (palivizumab), intravenous immune globulin (IGIV), or respiratory syncytial virus (RSV)-polyclonal-hyperimmune-globulin (RSV-IG as Respigam®, RI-001, RI-002) are used with ribavirin in RSV-infected immunocompromised patients, with debated efficacy. Palivizumab-resistance (PR) can arise during treatment of persistent infections in this population. RSV-IG may confer benefit in PR-RSV infection.
View Article and Find Full Text PDFArticle Synopsis
- This study investigated the oral RSV fusion protein inhibitor AK0529 for treating infant patients hospitalized with respiratory syncytial virus (RSV) infection, as current therapies are ineffective.
- In a Phase 2 trial, infants were given AK0529 or a placebo, with no significant safety issues reported and promising results showing reduced viral load and respiratory symptoms with the higher dose of AK0529.
- Overall, AK0529 was well-tolerated and indicated a potential for effective treatment in reducing RSV-related morbidity in young children.
Respiratory syncytial virus (RSV) is the leading, global cause of serious respiratory disease in infants and is an important cause of respiratory illness in older adults. No RSV vaccine is currently available. The RSV fusion (F) glycoprotein is a key antigen for vaccine development, and its prefusion conformation is the target of the most potent neutralizing antibodies.
View Article and Find Full Text PDF